Globus Medical (GMED) to Release Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of $0.74 per share and revenue of $646.19 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Globus Medical Stock Up 0.9 %

GMED stock opened at $84.72 on Wednesday. The firm’s fifty day simple moving average is $86.67 and its two-hundred day simple moving average is $78.76. The stock has a market capitalization of $11.54 billion, a price-to-earnings ratio of 126.45, a price-to-earnings-growth ratio of 1.68 and a beta of 1.19. Globus Medical has a twelve month low of $49.33 and a twelve month high of $94.93.

Insider Buying and Selling at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Kelly Huller sold 2,500 shares of Globus Medical stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Insiders own 18.54% of the company’s stock.

Wall Street Analysts Forecast Growth

GMED has been the subject of several analyst reports. Royal Bank of Canada raised their target price on shares of Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $80.00 to $97.00 in a report on Thursday, January 9th. Stifel Nicolaus lifted their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Truist Financial lifted their price objective on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.91.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.